RLYB

RLYB

Rallybio Corp

Rev โ€”top 1%5Y
Hold

Rallybio Corp develops therapies for severe and rare diseases, focusing on products like RLYB116, an inhibitor for complement dysregulation, and RLYB332, an antibody for severe anemia. It partners with AbCellera and Johnson & Johnson for further innovations.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$121today

Score Overview

1 Year
Score
Net Growth12.93%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth83.37%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend40%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth83.37%
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Rallybio Corp fundamental performance

Across Rallybio Corp's full reported history, from 2021 to 2025, revenue grew from $ 0.00 to $ 858K and net income went from -$ 47M to -$ 8M. Revenue increased in 40% of the years measured; net income in 60%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 16.59โ€”
1 Year2025-08-12
$ 4.03311.70%
5 Years2021-08-12
$ 137.20-87.91%
All Time2021-07-29
$ 112.80-85.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 858K-$ 7M$ 46M
2025$ 858K-$ 8M$ 54M
2024$ 636K-$ 57M$ 65M
2023$ 0.00-$ 74M$ 109M
2022$ 0.00-$ 66M$ 168M
IPO2021$ 0.00-$ 47M$ 175M

Explore beyond RLYB

You're looking at Rallybio Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies